secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2026-08-05T11:05:09+00:00
Accession:  0000059478-26-000077
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q2 revenue up 48% to $23.0B; raises full-year guidance
------------------------------------------------------------

- Q2 2026 revenue $22,974M (+48% YoY); reported EPS $7.94 (+26%), non-GAAP EPS $8.38 (+33%).
- Full-year revenue guidance raised to $85.0-87.0B; non-GAAP EPS guidance $35.50-$36.50 (up $2.78 midpoint).
- Q2 EPS includes $3.03/share of acquired IPR&D charges from business development activity.
- Completed acquisitions of Orna, Ajax, Centessa, Kelonia; post-quarter added infectious disease assets and AtaiBeckley.
- Committed $4.5B to expand Indiana manufacturing sites; retatrutide Phase 3 data complete for global registrations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/0000059478-26-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/lly-20260805.htm
  HTML page:      https://secwatch.observer/filing/0000059478-26-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer